Evolving Perspectives on Diagnostic Imaging in Advanced Prostate Cancer

Learn how PSMA PET reshapes prostate cancer staging, outperforms CT and bone scans, and finds recurrence even at very low PSA.

How teams use PSMA PET to stage prostate cancer: who orders, who reads, and how tumor boards refine treatment when findings conflict.

In ‘Expanding Clinical Use of PSMA PET in Advanced Prostate Cancer,’ our experts delve into how PSMA PET imaging is being incorporated into treatment decisions for patients with advanced and metastatic prostate cancer.

This episode, titled ‘Clinical Considerations for PSMA PET Agents in Advanced Prostate Cancer,’ the expert faculty review the currently FDA-approved PSMA PET diagnostic agents and their labeled indications, which are largely similar and include initial staging, biochemical recurrence, and evaluation for radioligand therapy.

In this episode, ‘Clinical Reliability of PSMA PET in Advanced Prostate Cancer,’ expert faculty examine the real-world reliability of PSMA PET imaging in evaluating tumor burden and disease extent in advanced prostate cancer.

In the final episode, ‘Advice for Integrating PSMA PET Imaging in Advanced Prostate Cancer,’ the panelists share practical advice for incorporating PSMA PET into prostate cancer clinics and workflows.

Learn how emerging advanced scans outpace CT and bone scans in finding micrometastatic prostate cancer and shaping treatment teamwork.

PSMA PET scans reshape prostate cancer care—learn who should interpret results, how reports vary, and why a team approach guides treatment.

PSMA PET interpretation standards evolve, with SUV reporting and staging differences across settings shaping therapy choices, sequencing, and metastasis-directed radiation decisions.

Real-world PSMA PET in prostate cancer reveals reporting variability, limits at low PSA, and mixed FDG PET value—what clinicians learn in practice.

New ASCO GU data compares fluorinated PSMA PET tracers, showing how bladder activity affects detection of prostate cancer recurrence at low PSA.

PSMA PET improves staging in advanced and recurrent prostate cancer, guiding shared decisions with expert interpretation and paving the way for theranostics.